Notably, in our model, treatment with a liposomal formulation containing both OVA and CpG, but not CpG alone, reversed established asthma, attenuating allergic lung inflammation and decreasing type 2 cytokine production in BAL without increasing airway IFN-γ production. Here, IFNG is linked to asthma.